Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Gilenya
Pharma
Eisai, AstraZeneca, Mitsubishi—Fierce Pharma Asia
CMS declined to revisit Leqembi coverage. AstraZeneca licensed an antibody-drug conjugate. Mitsubishi won a royalty case against Novartis. Plus more.
Angus Liu
Feb 24, 2023 8:45am
Mitsubishi scores $940M from Novartis in arbitration case
Feb 17, 2023 4:40pm
Novartis takes Gilenya patent case to Supreme Court
Jan 24, 2023 1:50pm
Novartis dealt another blow in ongoing Gilenya patent feud
Oct 14, 2022 9:49am
Novartis will turn to SCOTUS to protect its Gilenya patent
Sep 21, 2022 11:09am
Judge dismisses whistleblower's Novartis kickback case—again
Sep 14, 2022 8:54am
